The ME RS prediction algorithm is the only online RS prediction tool with an elaborative application of clinicopathologic parameters to assess a reliable recurrence score comparable to ODX prediction scores.[26] Similarly, preclinical data also suggests that the expression of AR may modify clinical outcomes in early BC with improved prognosis in ER+ and poorer prognosis in ER− disease.[27,28] The findings are preliminary but suggest a positive correlation between ME scores and AR+ expression. This evidence concerns the gene AR and breast cancer.